Axsome Therapeutics, Inc. (AXSM)
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer's Launch Gains Traction
Axsome Therapeutics NASDAQ: AXSM executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer's disease agitation, while management expects operating expenses to remain relatively stable in the second half of the year.
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics NASDAQ: AXSM executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference.
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company's deep pipeline may help it launch newer products and post consistent revenue growth for a while.
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability.
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.92 per share a year ago.
